GA101 (a Novel Anti-CD20 Monoclonal Antibody)-Induced Lichenoid Eruption

Introduction Obinutuzumab (GA101) is a novel anti-CD20 monoclonal antibody that has been shown to be effective for the treatment of non-Hodgkin's lymphoma, and is currently being evaluated in phase 3 clinical trials. The side-effect profile of the drug is not yet well established.Case report The authors report a case of a 62-year-old patient who developed widespread lichenoid eruption as a result of GA101 treatment for his follicular non-Hodgkin's lymphoma.Conclusion This is the first case report of cutaneous side effects of GA101.